Ask Michael Burke Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Knighty Tin who wrote (61248)	6/3/1999 11:42:00 AM
From: scaram(o)uche	Read Replies (1) of 132070

Thursday June 3, 10:50 am Eastern Time Company Press Release SOURCE: Duramed Pharmaceuticals, Inc. Duramed Receives Patent for Tablet Composition of Cenestin * Patent Reinforces Value of Slow Release Composition of Duramed's Hormone Products * Patent Covers Cenestin/Medroxyprogesterone Combination as Well as Other Anticipated Cenestin Combination Products Through July 26, 2015 * Patent is a Significant Part of Duramed's Female Healthcare Agenda ************* Thanks for the lead, Michael. Am studying it. Peter.... thanks for the commentary. I honestly believe that liquidity will come back for many of the "good science" companies, or that they'll get picked off near-term at nice premiums. I continue to believe that MLNM, for example, should use its strong currency, such that a "good/big science" biotech can pick off the "good/little science" biotechs. Cheers! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next